CA2768772A1 - Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients - Google Patents
Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients Download PDFInfo
- Publication number
- CA2768772A1 CA2768772A1 CA2768772A CA2768772A CA2768772A1 CA 2768772 A1 CA2768772 A1 CA 2768772A1 CA 2768772 A CA2768772 A CA 2768772A CA 2768772 A CA2768772 A CA 2768772A CA 2768772 A1 CA2768772 A1 CA 2768772A1
- Authority
- CA
- Canada
- Prior art keywords
- hepatitis
- treatment
- subject
- nucleic acid
- polymorphic marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 102
- 208000006454 hepatitis Diseases 0.000 title description 4
- 231100000283 hepatitis Toxicity 0.000 title description 3
- 208000005176 Hepatitis C Diseases 0.000 claims abstract description 128
- 238000011282 treatment Methods 0.000 claims abstract description 99
- 230000004044 response Effects 0.000 claims abstract description 66
- 102100020992 Interferon lambda-3 Human genes 0.000 claims abstract description 46
- 230000002269 spontaneous effect Effects 0.000 claims abstract description 40
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 claims abstract description 38
- 102100020990 Interferon lambda-1 Human genes 0.000 claims abstract description 37
- 239000000523 sample Substances 0.000 claims description 105
- 108020004707 nucleic acids Proteins 0.000 claims description 76
- 102000039446 nucleic acids Human genes 0.000 claims description 76
- 150000007523 nucleic acids Chemical class 0.000 claims description 76
- 101001002466 Homo sapiens Interferon lambda-3 Proteins 0.000 claims description 45
- 239000003550 marker Substances 0.000 claims description 44
- 239000012472 biological sample Substances 0.000 claims description 40
- 230000003612 virological effect Effects 0.000 claims description 40
- 229940079322 interferon Drugs 0.000 claims description 35
- 102210007160 rs8099917 Human genes 0.000 claims description 32
- 208000010710 hepatitis C virus infection Diseases 0.000 claims description 31
- 208000006154 Chronic hepatitis C Diseases 0.000 claims description 30
- 108010050904 Interferons Proteins 0.000 claims description 27
- 102000014150 Interferons Human genes 0.000 claims description 27
- 102210008190 rs12980275 Human genes 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 9
- 239000003443 antiviral agent Substances 0.000 claims description 8
- 229960000329 ribavirin Drugs 0.000 claims description 8
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 8
- 210000000349 chromosome Anatomy 0.000 claims description 7
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 7
- 238000011269 treatment regimen Methods 0.000 claims description 7
- 238000001514 detection method Methods 0.000 abstract description 8
- 102100020989 Interferon lambda-2 Human genes 0.000 abstract description 6
- 101710099621 Interferon lambda-3 Proteins 0.000 abstract description 3
- 101710099622 Interferon lambda-2 Proteins 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 241000711549 Hepacivirus C Species 0.000 description 54
- 108700028369 Alleles Proteins 0.000 description 50
- 108020004414 DNA Proteins 0.000 description 43
- 238000003556 assay Methods 0.000 description 34
- 238000009396 hybridization Methods 0.000 description 23
- 239000002773 nucleotide Substances 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 230000003321 amplification Effects 0.000 description 19
- 238000003199 nucleic acid amplification method Methods 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 230000002068 genetic effect Effects 0.000 description 14
- 206010016654 Fibrosis Diseases 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 239000000969 carrier Substances 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000054766 genetic haplotypes Human genes 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 230000004761 fibrosis Effects 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 206010066901 Treatment failure Diseases 0.000 description 6
- 102000054765 polymorphisms of proteins Human genes 0.000 description 6
- 101100396576 Gallus gallus IFNB gene Proteins 0.000 description 5
- 208000037581 Persistent Infection Diseases 0.000 description 5
- 238000003491 array Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108020005345 3' Untranslated Regions Proteins 0.000 description 4
- 101001002469 Homo sapiens Interferon lambda-2 Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000012502 diagnostic product Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 238000003205 genotyping method Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 239000003298 DNA probe Substances 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- IWUCXVSUMQZMFG-DJSMDIAISA-N 1-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=CN1[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-DJSMDIAISA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 101100232738 Gallus gallus IFNL3 gene Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000002698 KIR Receptors Human genes 0.000 description 2
- 108010043610 KIR Receptors Proteins 0.000 description 2
- 238000007476 Maximum Likelihood Methods 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 206010058874 Viraemia Diseases 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000012098 association analyses Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 208000020403 chronic hepatitis C virus infection Diseases 0.000 description 2
- 108010041758 cleavase Proteins 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000012317 liver biopsy Methods 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000006853 reporter group Chemical group 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 238000001216 nucleic acid method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH01201/09 | 2009-07-31 | ||
| CH12012009 | 2009-07-31 | ||
| US28253810P | 2010-02-26 | 2010-02-26 | |
| US61/282,538 | 2010-02-26 | ||
| PCT/IB2010/053139 WO2011013019A1 (en) | 2009-07-31 | 2010-07-09 | Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2768772A1 true CA2768772A1 (en) | 2011-02-03 |
Family
ID=42727569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2768772A Abandoned CA2768772A1 (en) | 2009-07-31 | 2010-07-09 | Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110165124A1 (enExample) |
| EP (1) | EP2459210A1 (enExample) |
| JP (1) | JP2013500713A (enExample) |
| KR (1) | KR20120040725A (enExample) |
| CN (1) | CN102665753A (enExample) |
| AU (1) | AU2010277239A1 (enExample) |
| BR (1) | BR112012001931A2 (enExample) |
| CA (1) | CA2768772A1 (enExample) |
| MX (1) | MX2012001058A (enExample) |
| WO (1) | WO2011013019A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5656159B2 (ja) * | 2009-08-24 | 2015-01-21 | 独立行政法人理化学研究所 | インターフェロン療法の効果予測用マーカー |
| RU2567806C2 (ru) * | 2009-12-22 | 2015-11-10 | ЯНССЕН Ар ЭНД Ди АЙРЛЭНД | Усиление прогностической ценности полиморфизма гена il28b в комбинации с количественной оценкой ip-10 в сыворотке при ответе на пегинторферон и рибавирин по сравнению с каждым из этих биомаркеров в отдельности |
| WO2012107584A1 (en) | 2011-02-11 | 2012-08-16 | Universite Pierre Et Marie Curie (Paris 6) | Methods for predicting outcome of a hepatitis virus infection |
| JP2014509628A (ja) * | 2011-03-31 | 2014-04-21 | ノバルティス アーゲー | Ｃ型肝炎ウイルス感染症を治療するためのアリスポリビル |
| US20140154209A1 (en) * | 2011-06-30 | 2014-06-05 | Centre Hospitalier Universitaire Vaudois | Polymorphisms associated with non-response to a hepatitis c treatment or susceptibility to non-spontaneous hepatitis c clearance |
| MX2014001355A (es) | 2011-08-03 | 2014-11-21 | Cytheris | Inmunoterapia contra el vhc. |
| JP2013074888A (ja) * | 2011-09-15 | 2013-04-25 | Arkray Inc | ＩＬ２８Ｂ（ｒｓ８０９９９１７）とＩＴＰＡ（ｒｓ１１２７３５４）の変異を検出する方法 |
| US20140271542A1 (en) * | 2011-10-05 | 2014-09-18 | The United States Of America As Represented By The Secretary, Department Of Health And Human Service | Genetic marker for predicting prognosis in patients infected with hepatitis c virus |
| GB2515942A (en) | 2011-10-21 | 2015-01-07 | Abbvie Inc | Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| PT107894A (pt) | 2011-10-21 | 2014-10-31 | Abbvie Inc | Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão. |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| AU2013240301B2 (en) | 2012-03-28 | 2017-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A novel interferon-lambda4 (IFNL4) protein, related nucleic acid molecules, and uses thereof |
| CN102816838A (zh) * | 2012-07-06 | 2012-12-12 | 吉林艾迪康医学检验所有限公司 | 用于检测丙型肝炎患者il28b snp12980275多态性的试剂盒 |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| CN108220424A (zh) * | 2018-02-05 | 2018-06-29 | 广州和康医疗技术有限公司 | 一种检测il28基因位点的方法及试剂盒 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5001050A (en) | 1989-03-24 | 1991-03-19 | Consejo Superior Investigaciones Cientificas | PHφ29 DNA polymerase |
| US5846717A (en) | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
| US5888780A (en) | 1992-12-07 | 1999-03-30 | Third Wave Technologies, Inc. | Rapid detection and identification of nucleic acid variants |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
| US6068818A (en) | 1993-11-01 | 2000-05-30 | Nanogen, Inc. | Multicomponent devices for molecular biological analysis and diagnostics |
| ZA959469B (en) | 1994-11-15 | 1996-05-15 | South African Druggists Ltd | Pharmaceutical composition |
| WO1997001603A1 (en) | 1995-06-26 | 1997-01-16 | Henkel Corporation | Methods of preparing inorganic pigment dispersions |
| US6001311A (en) | 1997-02-05 | 1999-12-14 | Protogene Laboratories, Inc. | Apparatus for diverse chemical synthesis using two-dimensional array |
| WO1999067641A2 (en) | 1998-06-24 | 1999-12-29 | Illumina, Inc. | Decoding of array sensors with microspheres |
| GB9817266D0 (en) | 1998-08-07 | 1998-10-07 | Imperial College | Method |
| US6429027B1 (en) | 1998-12-28 | 2002-08-06 | Illumina, Inc. | Composite arrays utilizing microspheres |
| JP2005204549A (ja) * | 2004-01-21 | 2005-08-04 | Hubit Genomix Inc | Ｃ型肝炎ウイルス感染者の経過に関する遺伝子およびその利用 |
| WO2006003654A2 (en) * | 2004-07-01 | 2006-01-12 | Medical Research Fund Of Tel Aviv Sourasky Medical Center | Methods and kits for predicting liver fibrosis progression rate in chronic hepatitis c patients |
| WO2010025380A2 (en) * | 2008-08-28 | 2010-03-04 | Vertex Pharmaceuticals Incorporated | Analysis of hcv genotypes |
| WO2010135649A1 (en) * | 2009-05-21 | 2010-11-25 | Schering Corporation | Genetic markers associated with interferon-alpha response |
-
2010
- 2010-07-09 BR BR112012001931A patent/BR112012001931A2/pt not_active IP Right Cessation
- 2010-07-09 JP JP2012522282A patent/JP2013500713A/ja active Pending
- 2010-07-09 CN CN2010800436612A patent/CN102665753A/zh active Pending
- 2010-07-09 CA CA2768772A patent/CA2768772A1/en not_active Abandoned
- 2010-07-09 KR KR1020127005379A patent/KR20120040725A/ko not_active Withdrawn
- 2010-07-09 WO PCT/IB2010/053139 patent/WO2011013019A1/en not_active Ceased
- 2010-07-09 AU AU2010277239A patent/AU2010277239A1/en not_active Abandoned
- 2010-07-09 MX MX2012001058A patent/MX2012001058A/es not_active Application Discontinuation
- 2010-07-09 EP EP10740746A patent/EP2459210A1/en not_active Withdrawn
- 2010-07-29 US US12/846,356 patent/US20110165124A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011013019A1 (en) | 2011-02-03 |
| KR20120040725A (ko) | 2012-04-27 |
| AU2010277239A1 (en) | 2012-02-02 |
| BR112012001931A2 (pt) | 2017-07-18 |
| JP2013500713A (ja) | 2013-01-10 |
| MX2012001058A (es) | 2012-06-19 |
| CN102665753A (zh) | 2012-09-12 |
| US20110165124A1 (en) | 2011-07-07 |
| EP2459210A1 (en) | 2012-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2768772A1 (en) | Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients | |
| Abe et al. | IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy | |
| US20120183497A1 (en) | Method of Determining Response to Treatment with Immunomodulatory Composition | |
| Serajee et al. | Polymorphisms in xenobiotic metabolism genes and autism | |
| Smith et al. | Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort | |
| US20070037183A1 (en) | Diagnostic and therapeutic target for macular degeneration | |
| RU2606759C2 (ru) | Однонуклеотидный полиморфизм на хромосоме 15, который позволяет прогнозировать восприимчивость к лечению вируса гепатита с | |
| WO2011146985A1 (en) | Method of determining response to treatment with immunomodulatory composition | |
| JP2013529068A (ja) | Ｈｃｖ治療における早期ウイルス応答の予測 | |
| US20140154209A1 (en) | Polymorphisms associated with non-response to a hepatitis c treatment or susceptibility to non-spontaneous hepatitis c clearance | |
| Abe et al. | Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state | |
| JP2023552199A (ja) | コロナウイルス感染症を発症するリスクが高い対象を特定する方法及びその治療法 | |
| US20140271542A1 (en) | Genetic marker for predicting prognosis in patients infected with hepatitis c virus | |
| EP2516674A1 (en) | Mutant ldl receptor gene | |
| Lange et al. | HLA class I allele associations with HCV genetic variants in patients with chronic HCV genotypes 1a or 1b infection | |
| WO2013030786A1 (en) | Method for diagnosing or predicting hepatocellular carcinoma outcome | |
| Class et al. | Patent application title: POLYMORPHISMS ASSOCIATED WITH NON-RESPONSE TO A HEPATITIS C TREATMENT OR SUSCEPTIBILITY TO NON-SPONTANEOUS HEPATITIS C CLEARANCE Inventors: Stephanie Bibert (Divonne-Les-Bains, FR) Pierre-Yves Bochud (Grandvaux, CH) Assignees: Centre Hospitalier Universitaire Vaudois | |
| HK1176284A (en) | Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients | |
| CN114540479A (zh) | 用于检测与耳聋相关的基因snp的组合物、试剂盒及检测方法 | |
| US20130203054A1 (en) | Antiviral treatment susceptibility gene and uses thereof | |
| JP5695181B2 (ja) | Ｈｃｖ治療成果を予測する一塩基多型 | |
| US20100284966A1 (en) | Methods and Compositions for Managing Resistance of Hepatitis C Virus to Immunosuppressant | |
| KR100658606B1 (ko) | Ｃ형 간염 바이러스의 유전자형 분석방법 | |
| WO2012145794A1 (en) | Method of determining response to treatment with immunomodulatory composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20150709 |